As circulating IFN-α appears to correlate with SLE disease activity, and possibly associate with certain disease manifestations (4–6), there is great interest to attain a readily accessible and standardised method to quantify IFN-α and introduce such assays into clinical practice (7). The gene discussed is IFNA1; the disease is systemic lupus erythematosus.